Management of Heart Failure with Reduced Ejection Fraction and Regional Wall Motion Abnormalities
This patient has HFrEF (LVEF 42%) with evidence of prior myocardial infarction (anterior wall severe hypokinesia and septal dyskinesis), and requires immediate initiation of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction, coronary angiography to assess for revascularization opportunities, and optimization of volume status. 1
Classification and Prognostic Assessment
This patient falls into the HFrEF category (LVEF <40-49% range, here 42%), which is critical because only in HFrEF have therapies been proven to reduce both morbidity and mortality. 1 The severely impaired global longitudinal strain (GLS -10%) indicates significant myocardial dysfunction beyond what the LVEF suggests, as normal GLS is typically -18% or better. 2
The regional wall motion abnormalities (anterior wall severe hypokinesia and septal dyskinesis) strongly suggest ischemic cardiomyopathy as the underlying etiology. 1
Immediate Management Priorities
1. Coronary Evaluation
- Coronary angiography is essential to determine if there is viable but hibernating myocardium that could benefit from revascularization. 1
- The pattern of anterior and septal involvement suggests left anterior descending artery territory disease
- Revascularization of viable myocardium can improve outcomes in ischemic cardiomyopathy
2. Initiate Guideline-Directed Medical Therapy
The ESC guidelines emphasize that specific pharmacological therapy for HFrEF is the cornerstone of treatment, as this is where mortality reduction has been demonstrated. 1 This includes:
- ACE inhibitor/ARB or ARNI (angiotensin receptor-neprilysin inhibitor)
- Beta-blocker
- Mineralocorticoid receptor antagonist
- SGLT2 inhibitor
3. Address Hemodynamic Abnormalities
Pulmonary Hypertension (PAP 49 mmHg):
- This elevated pulmonary artery pressure reflects increased left ventricular filling pressures and is associated with worse outcomes 3
- Optimization of GDMT and volume management should reduce PAP over time
Mitral Regurgitation:
- The mild MR is functional (secondary to ventricular dysfunction and dilatation) rather than organic valve disease 3
- In patients with advanced systolic heart failure, the severity of MR correlates with ventricular dilatation, diastolic dysfunction, and pulmonary hypertension 3
- Functional MR at this severity (mild) does not require specific intervention beyond treating the underlying HFrEF 4
- GDMT and potential revascularization may reduce MR severity through reverse remodeling 5
4. Diastolic Dysfunction Management
The Grade I diastolic dysfunction, while present, is common in HFrEF patients. 1 The multiparametric assessment of diastolic function is complex, but in this context of clear systolic dysfunction, the primary focus should be on HFrEF treatment rather than isolated diastolic dysfunction management. 2, 6
Common Pitfalls to Avoid
- Do not delay coronary evaluation in patients with regional wall motion abnormalities suggesting ischemic etiology—viable myocardium may be salvageable
- Do not focus excessively on the mild valvular regurgitation—the MR and TR are functional and will likely improve with HFrEF treatment 3, 4
- Do not be falsely reassured by the LVEF of 42%—the severely reduced GLS (-10%) indicates worse myocardial function than the LVEF suggests 2
- Do not overlook the need for device therapy evaluation—if LVEF remains ≤35% after 3 months of optimal medical therapy, the patient may be a candidate for ICD or CRT-D depending on QRS duration